Deliver Your News to the World

Biogen Idec Announces William H. Rastetter To Retire As Executive Chairman


WEBWIRE

Bruce Ross to Become Non-Executive Chairman

Cambridge, MA and San Diego, CA - December 7, 2005 - Biogen Idec (NASDAQ: BIIB) announced today that William H. Rastetter, Ph.D., will retire as Executive Chairman of the company effective at the end of the year. Bruce Ross, presently chairman of the company’s compensation committee, will become non-executive chairman of the Board of Directors effective January 1, 2006. James C. Mullen will continue as President and Chief Executive Officer of Biogen Idec.

“I am proud of all that we have accomplished in implementing the integration of Biogen and IDEC and establishing a platform for future success,” said Dr. Rastetter. “I want to thank the countless patients, employees and shareholders with whom I’ve had the pleasure to work with over many years. You have honored me with your trust and inspired me to help those in need. I am grateful for your support.”

“It was Bill Rastetter’s drive and unyielding commitment to those we serve that resulted in bringing RITUXAN® (rituximab), the world’s leading cancer therapeutic, to patients across the globe,” said Mr. Ross. “His leadership is proof that one man can make a major difference in the lives of many.”

Bruce Ross is currently President of Cancer Rx, a healthcare consulting firm. Mr. Ross was previously Chief Executive Officer of the National Comprehensive Cancer Network, an association of 19 of the largest cancer centers in the United States. He previously held senior management positions, during a 27-year career at Bristol-Myers Squibb. Mr. Ross began serving as a Director of IDEC in 1997.
About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.



WebWireID6608





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.